AGP Executive Report
Last update: 8 hours agoCBD Access: Kazmira Therapeutics says a new telemedicine partnership will connect patients with clinician-prescribed, THC-free CBD made by a licensed pharmacy. The company is positioning the service for a tighter regulatory climate, though its claims about future compliance are its own. Federal Rules: The DEA has paused marijuana rescheduling while a judge considers a government report on how scheduling decisions are handled. The delay does not change federal law; separate hemp restrictions due in December could also put many intoxicating hemp products on the market at risk. State Impact: South Dakota’s attorney general says federal rescheduling would not disrupt the state’s medical cannabis program, leaving future changes to lawmakers or voters. Prescription Safety: After an inquest linked prescribed cannabis use to a man’s mental decline before his death, a coroner urged a pause on prescribing cannabis products to new patients with mental health conditions while guidance is reviewed.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
